Comparative Pharmacology
Head-to-head clinical analysis: MOZOBIL versus PLERIXAFOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOZOBIL versus PLERIXAFOR.
MOZOBIL vs PLERIXAFOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Plerixafor is a selective antagonist of the chemokine receptor CXCR4. It blocks the binding of stromal cell-derived factor-1α (SDF-1α) to CXCR4, disrupting the retention of hematopoietic stem cells in the bone marrow and promoting their mobilization into peripheral blood.
Plerixafor is a bicyclam molecule that reversibly inhibits the binding of stromal cell-derived factor-1α (SDF-1α) to its cognate receptor CXCR4 on hematopoietic stem cells, thereby blocking the retention signal and mobilizing stem cells from the bone marrow into the peripheral blood.
0.24 mg/kg subcutaneously once daily for up to 5 consecutive days.
0.24 mg/kg subcutaneously once daily for up to 4 consecutive days.
None Documented
None Documented
Terminal elimination half-life is 5–6 hours in healthy adults; may be prolonged in patients with renal impairment (up to 11 hours in severe renal dysfunction).
Terminal half-life: 3-5 hours in healthy adults; prolonged in renal impairment (up to 15 hours in severe cases).
Primarily biliary and fecal excretion (approximately 75% of dose); renal excretion accounts for ~25% as unchanged drug and metabolites.
Renal: 70% unchanged; fecal: 20% (as metabolites); biliary: <10%.
Category C
Category C
Hematopoietic Stem Cell Mobilizer
Hematopoietic Stem Cell Mobilizer